Washington, DC, Oct. 01, 2025 (GLOBE NEWSWIRE) -- On this Urticaria Day (UDAY), the Asthma and Allergy Foundation of America (AAFA), We CU, and The Mast Cell Disease Society (TMS) aim to raise ...

Treatment for chronic hives lasting at least 6 weeks may include one or more types of medication, as well as certain lifestyle changes.

The Food and Drug Administration (FDA) has approved Rhapsido ® (remibrutinib) for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H 1 ...

Novartis received approval from the Food and Drug Administration for Rhapsido (remibrutinib), an oral treatment for adults with chronic ...

Pressure urticaria is a type of chronic urticaria that causes recurring hives from pressure applied to your skin. It may be treated with a combination of trigger avoidance and medications. Better ...

Hives are one of those things that you hear about so often that it feels like you should know what they are, how to spot them and how to treat them. But the truth is that many of us don’t really know ...

The FDA approved oral remibrutinib (Rhapsido) as a second-line treatment for chronic spontaneous urticaria (CSU), or chronic ...

The first oral BTK blocker for chronic spontaneous urticaria, Rhapsido offers a more convenient treatment option for patients ...

The FDA today approved remibrutinib (Rhapsido; Novartis), a highly selective Bruton tyrosine kinase inhibitor (BTKi), for the ...

Novartis AG won US approval for a new treatment for a hives-like skin condition, bolstering the Swiss drugmaker’s push into ...

The FDA approved remibrutinib, the first oral treatment for adults with persistent chronic spontaneous urticaria despite H1 ...

Remibrutinib is the first Bruton tyrosine kinase inhibitor approved by the FDA for chronic spontaneous urticaria.